Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA-204 (miR-204)
- Target
- miR-204
- Molecular classification
- MicroRNA, Non-coding RNA
01
Overview
MicroRNA-204 (miR-204) is a highly conserved, small non-coding RNA molecule predominantly expressed in the eye, blood vessels, kidney, and other tissues, where it plays a crucial role in post-transcriptional gene regulation. In humans, it is encoded by the MIR204 gene, located in an intron of the TRPM3 gene on chromosome 9. miR-204 is essential for normal development and function of the lymphatic system, modulates endothelial and microglial cell homeostasis, and protects retinal structure and function by regulating phagolysosomal activity and lipid metabolism. Dysregulation of miR-204 is implicated in various pathophysiological states, including cardiovascular and renal diseases, inherited retinal diseases, and several cancer types. While there are currently no approved drugs specifically targeting miR-204, its clear functional roles in disease have made it a focus for biomarker discovery and therapeutic exploration[1][2][3][4].
- Other names
- miR-204MIR204hsa-mir-204MIRN204RDICCmiRNA204mir-204
02
Mechanism of action
Post-transcriptional silencing of target mRNAs (e.g., NFATC1 in lymphatic endothelium, TGFBR2 in microglia) Regulation of gene networks involved in cell differentiation, metabolic homeostasis, and inflammation[2][3]
03
Biological functions
Regulation of gene expression (post-transcriptional)Modulation of lymphangiogenesis (lymphatic vessel development)Regulation of endothelial and smooth muscle cell functionRegulation of retinal pigment epithelium (RPE) homeostasisControl of phagolysosomal activityRegulation of cell metabolism, including lipid metabolism in microglia and RPE cells[1][2][3][4]
04
Disease associations
Cardiovascular disease (hypertension, pulmonary arterial hypertension)Renal diseases (hypertensive and diabetic renal injury)Eye diseases (inherited retinal degeneration, coloboma, impaired RPE function)Cancer (dysregulated in some cancer contexts, role in EMT)Other: Potential involvement in neurodegenerative processes via retinal microglia regulation[1][2][3][4]
05
Safety considerations
Off-target effects if targeted therapeutically (due to broad gene regulation)Tissue-specific roles: manipulation could produce unintended effects in non-target tissues (e.g., impacting both cardiovascular and ocular systems)Potential immune activation with synthetic oligonucleotide therapies
06
Interacting drugs
None directly approved targeting miR-204 specifically as of current knowledge
1 more in the full profile.
07
Biomarkers
miR-204 levels in tissues or extracellular vesicles as biomarker for cardiovascular, renal, and retinal diseasesMay serve as a disease biomarker in certain cancers and eye diseases[1][3][4]
Beyond the preview
Go deeper on MicroRNA-204 (miR-204).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA-204 (miR-204).